<< Back to Summary 
The results of this study will be submitted to the FDA. What action do you think the FDA should take based on this study?
#Response DateOther (please specify)
1.3/3/2008 3:00:00 PMInclude pharmacogenomics and prior episodes
2.3/3/2008 4:28:00 PMMandate publication of all drug company sponsored trials
3.3/5/2008 4:49:00 AMStudies should have minimal exclusion criteria. Because of the very nature of RCTs the patients are not representative of the actual clinic population. While RCTs are gold standards for establishing efficacy, next level trials have to be simple, pragmatic and closer to actual clinic practice.
4.3/5/2008 6:07:00 PMat most consider adding additional info to package insert